Nowadays, CheckMate 025 was a trial comparing Nivolumab to Everolimus, showing no significant differences in progression free survival (PFS). However, it did show a higher objective response rate (ORR) for all MSKCC risk groups for Nivolumab compared to Everolimus (favourable 24% vs. 8%, Intermediate 25% vs. 5% and poor 27% vs. 3%).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Dr. Hammers concluded that the future holds many combination possibilities for these different medications in RCC, potentially resulting in a non-immune synergy.
Presented By: Hans Hammers, MD, PhD, UT Southwestern Medical Center
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
at the 2017 Bladder Cancer Academy - June 9 - 10 - Schaumburg, Illinois, USA